When you take a rapid strep test at urgent care or a pharmacist runs a fingerstick glucose check, the test is happening under a CLIA waiver, and that is why it can be done outside a full clinical laboratory. CLIA, the Clinical Laboratory Improvement Amendments, is the federal framework that sets quality standards for laboratory testing on human specimens. Most testing falls under tiered requirements based on complexity. But a slice of tests, the simplest and lowest-risk, can be run under a 'certificate of waiver,' which is what makes point-of-care and near-patient testing practical.

The criteria are not vague. They are written into 42 CFR 493.15, the regulation governing laboratories performing waived tests. It states that tests for a certificate of waiver must meet specific descriptive criteria, and it lists them.

"Test systems are simple laboratory examinations and procedures which— (1) Are cleared by FDA for home use; (2) Employ methodologies that are so simple and accurate as to render the likelihood of erroneous results negligible; or (3) Pose no reasonable risk of harm to the patient if the test is performed incorrectly."— 42 CFR 493.15, source

What the three criteria actually require

Read the criteria closely and they describe a coherent risk philosophy. The first, cleared by the FDA for home use, captures tests already deemed simple enough for an untrained consumer to run at home, an over-the-counter pregnancy test is the archetype. The second turns on the method itself: so simple and accurate that erroneous results are negligible, not merely uncommon. The third is a safety backstop: even if the test were performed incorrectly, it poses no reasonable risk of harm to the patient. A test does not have to satisfy all three; meeting the descriptive criteria is what qualifies a test system as waived.

The regulation then enumerates an initial list of qualifying test categories, and it reads like the contents of a basic clinic drawer: non-automated dipstick or tablet reagent urinalysis for analytes such as glucose, ketone, protein, pH, and specific gravity; non-automated fecal occult blood; visual ovulation tests for luteinizing hormone; and urine pregnancy tests by visual color comparison, among others. The list is not frozen, the regulation provides a mechanism to add tests to it, which is how the universe of waived tests has grown over time as new simple systems clear the FDA.

Who decides, and what a waiver does and does not mean

A point that trips people up: CLIA and the FDA are doing two different jobs here. CLIA, administered by the Centers for Medicare & Medicaid Services, governs the laboratory, what certificate it holds and what quality requirements apply to its testing. The FDA, by contrast, is the agency that evaluates whether a specific test system meets the waiver criteria, typically as part of, or alongside, the device's own clearance. So when a manufacturer says a test is 'CLIA waived,' it means the FDA has categorized that test as meeting the 493.15 criteria, and a lab holding a certificate of waiver may run it.

It is equally important to be precise about what the waiver does not do. A certificate of waiver exempts a lab from most of the routine CLIA requirements, such as proficiency testing and certain personnel and quality-control standards, that apply to moderate- and high-complexity testing. It does not exempt the lab from all oversight: waived labs must still enroll, follow the manufacturer's instructions, and remain subject to inspection. And the waiver is about simplicity of the test, not about the importance of the result; a waived test can still inform a meaningful clinical decision. The waiver speaks to how the test is run and how forgiving it is, not to how much its answer matters.

The clean way to hold all of this together is to separate the test from the place. The FDA decides whether a diagnostic test system is simple and low-risk enough to be waived, measured against the three criteria in 42 CFR 493.15. CLIA, through a certificate of waiver, then decides what a laboratory holding that certificate is permitted to run. The result is the reason a simple test can travel out of the central lab and into a pharmacy, a clinic, or a kit on a drugstore shelf, while the more complex testing stays under CLIA's fuller set of controls.

Waived, moderate, and high complexity

The waiver sits at the bottom of a complexity ladder, and seeing the whole ladder makes the waiver's place clearer. CLIA sorts non-waived testing into 'moderate complexity' and 'high complexity,' each carrying progressively stricter requirements for personnel qualifications, quality control, and proficiency testing. A waived test, by contrast, is exempt from most of those routine requirements precisely because it met the simplicity-and-accuracy bar in 493.15. The categorization is not a judgment about how valuable a test is; it is a judgment about how much can go wrong in performing it and how forgiving the method is. A test that demands careful technique, calibration, and trained interpretation lands in moderate or high complexity even if its result is routine; a test a layperson can run reliably at home lands in the waived tier even if its result is clinically meaningful.

That framing also explains why the waived list grows but does so deliberately. The regulation enumerates an initial set of qualifying examinations and builds in a mechanism to add tests as new simple systems clear the FDA, which keeps the list current without diluting the criteria. Each addition still has to clear the same bar: simple, accurate to the point that error is negligible, or harmless if performed incorrectly. So the waiver is best understood not as a loophole but as a calibrated exemption, one the FDA grants test-by-test against fixed criteria, and one CLIA then honors at the laboratory level through the certificate of waiver. The two agencies, working from the same 493.15 criteria, are what make point-of-care diagnostics both widely available and accountable to a federal standard.